Opinion|Videos|May 2, 2025
Weighing QoL and Toxicity in 1L EGFRm NSCLC Treatment Decisions
Panelists discuss how quality-of-life (QoL) considerations and individual toxicity profiles significantly impact first-line (1L) treatment decisions, with different regimens having distinct adverse effect profiles.
Advertisement
Episodes in this series
Quality-of-Life and Toxicity Considerations
Main Discussion Topics:
- Comparative toxicity profiles of available treatment regimens
- Impact of adverse effects on patient QoL
- Prophylactic strategies to mitigate treatment-related adverse events
Key Points for Physicians:
- Osimertinib monotherapy is extremely well tolerated with minimal impact on daily life
- FLAURA2 (chemotherapy + osimertinib) has more intensive induction followed by manageable maintenance
- Amivantamab + lazertinib has unique toxicities, including scalp rash, paronychia, hypoalbuminemia, and venous thromboembolism risk
Notable Insights:
Prophylactic strategies (COCOON for dermatologic toxicities; SKIPPirr for infusion reactions, anticoagulation) can significantly reduce adverse events with amivantamab/lazertinib.
Clinical Significance:
Selection of therapy requires careful assessment of toxicity profiles in the context of patient comorbidities, support systems, and preferences regarding appearance and lifestyle impact.
Advertisement
Related to this article
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.
Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5